SEC Form 4 · accession 0001193125-26-300163
Aktis Oncology, Inc. · AKTS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shulamit Ron-Bigger
Officer — Chief Operating Officer
Period of report
Jul 8, 2026
Accepted (ET)
Jul 10, 2026 · 6:11 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002035832
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 8, 2026 | M | 50,000 | $3.66 | A | 50,000 | D | |
| Common StockF1 | Jul 8, 2026 | S | 15,800 | $27.1317 | D | 34,200 | D | |
| Common StockF2 | Jul 8, 2026 | S | 30,000 | $27.9379 | D | 4,200 | D | |
| Common StockF3 | Jul 8, 2026 | S | 4,200 | $28.7476 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $3.66 | Jul 8, 2026 | M | 50,000 | D | — | Oct 30, 2032 | Common Stock | 50,000 | 217,888 | D |
Explanation of responses
- F1The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.5200 to $27.5100, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.5200 to $28.4700, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.7300 to $28.7600, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F425% of the original number of shares subject to the option vested on September 19, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.